Impressive Clinical Data from Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Impressive Clinical Data from Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Impressive Clinical Data from Actinium Presented at the American Society of Hematology (ASH) Annual Meeting!

Good day everyone,

Today we are continuing coverage of, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a late stage biopharmaceutical company.

Current price $10.98 per share

ATNM shares gapped at the open in Monday’s trading session, opening at $11.65/share before turning back to fill that gap and consolidate at the current price.

Those of us, including many of our members, have watched the progress of Actinium for a while and we believe that ATNM has reached a milestone in its clinical trials that may be a catalyst for the company shares.

The news from the American Society of Hematology (ASH) Annual Meeting that we talked about earlier is coming out. The conference began over the weekend and ends Tuesday the 8th. We want to discuss some of the ATNM highlights from the conference. The data presented at the conference is great news for the company and shareholders alike.

The news from the ASH Meeting has also inspired at least three analysts to update their coverage on ATNM with reports dated Monday, December 7th. We’ve included target prices and highlights from the analyst’s reports further down in this newsletter. All three analysts cited below have rated ATNM shares “buy to outperform”.

Iomab-B via the monoclonal antibody BC8, targets CD45, is an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Lomab-B is in a phase III clinical trial and is ATNM’s lead product candidate

Through 75% of patient enrollment, 100% (49/49) of patients receiving a therapeutic dose of Iomab-B in SIERRA have successfully proceeded to Bone Marrow Transplant (BMT) compared to 16% (9/56) of patients in the control arm who received physician’s choice of salvage therapies.

Further, the SIERRA trial indicated lower rates of non-relapse transplant related mortality, sepsis, infections, and mucositis reported in patients receiving Iomab-B compared to patients on the control arm receiving salvage therapies

The release of these data is a huge affirmation of lomab-B and the SIERRA trial. ATNM has been in the SIERRA trial for a long time, devoting a significant amount of its resources and effort. The data also present a giant leap in treatment potential for those suffering from Refractory Acute Myeloid Leukemia and candidates for Bone Marrow Transplant.

In another presentation at the ASH conference the company discussed data from its Phase I trial of Actimab-A CLAG-M Chemotherapy in Relapsed/Refractory AML, which is being conducted at the Medical College of Wisconsin. The data revealed:

100% remission rate in the third dose cohort of 0.75 μCi/kg of Actimab-A (lintuzumab-225Ac) and standard regimen of CLAG-M

70% of patients achieving remission were MRD negative with remissions and MRD negativity reported in all dose cohorts.

We have linked a couple press releases below, announcing these data releases in more detail:

Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment

Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial

Though the ASH Meeting is still ongoing at this writing, the analysts are already covering the ATNM presentation

William Blair – “Our belief is that the final results (at interim or at primary analysis) of the ongoing Phase III SIERRA trial will likely be one of the most impactful events in the company’s history. Based on our discounted cash flow analysis, we ascribe roughly a $11.50 per share fair value to the Iomab-B program, as a targeted conditioning regimen candidate for acute myeloid leukemia. Given the favorable risk/reward profile, we reiterate our Outperform rating on Actinium shares.”

Jones Trading – “Our average of DCF/NPV/PE based valuations indicate $40 price target. Key contributors to our price target in NVP model are Iomab-B in r/r AML — contributing $26/share, followed by $6/share from Actimab in r/r MDS and $2/share from IomabB in r/r MM. Cash ($4/share) and technology value ($8/share) contribute to the remainder of our price target.”

H.C. Wainwright & Co. – “We reiterate our Buy rating and $65 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is primarily based on the initial Iomab-B opportunity for AML, representing 97% contribution currently (59% U.S. and 38% E.U.) with the remainder coming from Actimab, which is in earlier stages of development.”

Actinium’s Clinical Trials

Actinium currently has multiple clinical trials ongoing including the Phase 1 Actimab-A CLAG-M and Phase 1/2 Actimab-A venetoclax combination trials and is exploring additional CD33 ARC combinations with other therapeutic modalities such as chemotherapy, targeted agents, or immunotherapy.

Let’s review some facts about ATNM that indicate growth potential:
Tiny float 12.7 million shares
Proprietary, patented technology
Late-stage successful clinical trial
High institutional ownership
Long term cash runway
Chart setup indicates potential breakout

While insider ownership is relatively low at ATNM, 44 institutions have accumulated over 22% of the company shares with six institutions owning over 100,000 shares each. These pros may see potential in ATNM.

Again, the data released at ASH for the Phase III SIERRA trial is a big milestone for ATNM combined with these analyst targets could act as a catalyst for the company shares in the near to mid-term.

Stay Tuned and stay informed,

The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated sixteen thousand five hundred dollars cash via bank wire by legends media llc for this weeks coverage of atnm. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.